Business Description
Emmaus Life Sciences Inc
NAICS : 325414
SIC : 2836
ISIN : US29137T1016
Total Employee Number:
33Description
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.03 | |||||
Equity-to-Asset | -3.63 | |||||
Debt-to-Equity | -0.47 | |||||
Debt-to-EBITDA | -74.01 | |||||
Interest Coverage | 0.05 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -24.05 | |||||
Beneish M-Score | -4.29 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -19.5 | |||||
3-Year EBITDA Growth Rate | 64.4 | |||||
3-Year EPS without NRI Growth Rate | 23.5 | |||||
3-Year Book Growth Rate | -9.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 68.89 | |||||
9-Day RSI | 61.8 | |||||
14-Day RSI | 58.44 | |||||
3-1 Month Momentum % | -11.38 | |||||
6-1 Month Momentum % | -11.38 | |||||
12-1 Month Momentum % | -17.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.08 | |||||
Quick Ratio | 0.06 | |||||
Cash Ratio | 0.02 | |||||
Days Inventory | 677.71 | |||||
Days Sales Outstanding | 70.41 | |||||
Days Payable | 2099.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.3 | |||||
Shareholder Yield % | 57.41 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93.35 | |||||
Operating Margin % | 3.23 | |||||
Net Margin % | -70.64 | |||||
EBITDA Margin % | -3.62 | |||||
FCF Margin % | -5.27 | |||||
OCF Margin % | -5.27 | |||||
ROA % | -39.81 | |||||
ROIC % | 0.64 | |||||
3-Year ROIIC % | -30.21 | |||||
ROC (Joel Greenblatt) % | -48.55 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.06 | |||||
EV-to-EBIT | -66.02 | |||||
EV-to-EBITDA | -73.45 | |||||
EV-to-Revenue | 2.66 | |||||
EV-to-Forward-Revenue | 20.28 | |||||
EV-to-FCF | -50.4 | |||||
Price-to-GF-Value | 1.09 | |||||
Price-to-Median-PS-Value | 0.03 | |||||
Earnings Yield (Greenblatt) % | -1.51 | |||||
FCF Yield % | -83.31 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:EMMA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Emmaus Life Sciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 12.029 | ||
| EPS (TTM) ($) | -0.13 | ||
| Beta | 5.4061 | ||
| 3-Year Sharpe Ratio | 0.56 | ||
| 3-Year Sortino Ratio | 32.1 | ||
| Volatility % | 63.12 | ||
| 14-Day RSI | 58.44 | ||
| 14-Day ATR ($) | 0.001236 | ||
| 20-Day SMA ($) | 0.010537 | ||
| 12-1 Month Momentum % | -17.12 | ||
| 52-Week Range ($) | 0.008 - 0.0172 | ||
| Shares Outstanding (Mil) | 70.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Emmaus Life Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Emmaus Life Sciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 134 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 43 days | ||
| General meeting for 2025 | 2026-07-01 | 0.01 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 0.01 (+0.00%) | ||
| Annual report for 2025 | 2026-03-31 | 0.02 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 22:00 | 0.02 (+2.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 0.01 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 0.02 (+8.77%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 0.01 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-04-14 18:25 | 0.02 (+0.00%) |
Show
Entries
Emmaus Life Sciences Inc Frequently Asked Questions
What is Emmaus Life Sciences Inc(EMMA)'s stock price today?
The current price of EMMA is $0.01. The 52 week high of EMMA is $0.02 and 52 week low is $0.01.
When is next earnings date of Emmaus Life Sciences Inc(EMMA)?
The next earnings date of Emmaus Life Sciences Inc(EMMA) is 2026-08-14 Est..
Does Emmaus Life Sciences Inc(EMMA) pay dividends? If so, how much?
Emmaus Life Sciences Inc(EMMA) does not pay dividend.
Guru Commentaries on OTCPK:EMMA
No articles.
Press Release
Articles on Emmaus Life Sciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers